MCMichelle Casey

Michelle Casey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle Casey has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis

    by Debananda Gogoi, Claudie Gabillard-Lefort, Rory Baird, Luke Forde, Mengxin Niu, Sara Waqas Ahmed, Cedric Gunaratnam, Michael Williamson, Michelle Casey, Emer P Reeves


  • Peptidyl-arginine deiminases – neutrophil derived proteins as anti-Pseudomonas aeruginosa agents in patients with cystic fibrosis

    by R Baird, D Gogoi, A Yusuf, G Murray, M Murphy, M Casey, E Reeves

    Introduction:Pseudomonas aeruginosa is the major respiratory pathogen in patients with cystic fibrosis (CF). Chronic infections result in accelerated pulmonary function decline. New effective therapeutic options are needed. Proteomic studies have identified peptidyl-arginine deaminases (PADs) within neutrophil granules, possibly indicating their involvement in microbial killing. Aims: We hypothesised that PADs participate in the vacuolar bacterial killing process of neutrophils. To assess this, PAD’s in-vitro bactericidal effect against P. aeruginosa and localisation in neutrophils was evaluated. Methods: In bacterial killing assays, P. aeruginosa (PA01) was exposed to increasing concentrations of PAD2, PAD4 or bactericidal permeability-increasing protein (BPI; positive control) and colony-forming units or optical density (600 nm) were recorded. Subcellular fractionation of neutrophils was performed by sucrose gradient ultracentrifugation following N2 cavitation. Presence of PADs in neutrophil compartments was assessed by western blot analysis. Results: In combination, 20 nM PAD2 and PAD4 killed 74±19% of P. aeruginosa in 1hr (p < 0.001). Post-32 min exposure, PAD2, PAD4 and BPI exhibited MIC50 values of 18.9, 10.4, and 7.0 nM respectively. PAD2 and PAD4 were localised to neutrophil primary granules. Together these results support the antimicrobial participation of PADs following degranulation into neutrophil phagosomes. Conclusion: PAD2 and PAD4 possess potent anti-pseudomonal activity, warranting further research to validate the use of PAD-based antimicrobial agents for CF patients. This study was supported by Pfizer Healthcare Ireland.

  • Alpha-1 Antitrypsin Therapy Modifies Neutrophil Adhesion in Patients with Obstructive Lung Disease

    by Tom McEnery, Michelle M. White, Debananda Gogoi, Orla Coleman, David Bergin, Bakr Jundi, Ryan Flannery, Fatima Abbas T. Alsaif, Sarah A. Landers, Michelle Casey, et al.

    Alpha-1 antitrypsin deficiency (AATD) is characterized by neutrophil-dominated inflammation resulting in emphysema. The cholesterol-rich neutrophil outer plasma membrane plays a central role in adhesion and subsequent transmigration to underlying tissues. This study aimed to investigate mechanisms of increased neutrophil adhesion in AATD and whether alpha-1 antitrypsin (AAT) augmentation therapy abrogates this effect. Plasma and blood neutrophils were donated by healthy controls (n = 20), AATD (n = 30), and AATD patients after AAT augmentation therapy (n = 6). Neutrophil membrane protein expression was investigated using liquid chromatography–tandem mass spectrometry. The effect of once-weekly intravenous AAT augmentation therapy was assessed by calcium fluorometric, μ-calpain, and cell adhesion assays. Decreased neutrophil plasma membrane cholesterol content (P = 0.03), yet increased abundance of integrin α-M (fold change 1.91), integrin α-L (fold change 3.76), and cytoskeletal adaptor proteins including talin-1 (fold change 4.04) were detected on AATD neutrophil plasma membrane fractions. The described inflammatory induced structural changes were a result of a more than twofold increased cytosolic calcium concentration (P = 0.02), leading to significant calcium-dependent μ-calpain activity (3.5-fold change; P = 0.005), resulting in proteolysis of the membrane cholesterol trafficking protein caveolin-1. Treatment of AAT-deficient individuals with AAT augmentation therapy resulted in increased caveolin-1 and membrane cholesterol content (111.8 ± 15.5 vs. 64.18 ± 7.8 μg/2 × 107 cells before and after treatment, respectively; P = 0.02), with concurrent decreased neutrophil integrin expression and adhesion. Results demonstrate an auxiliary benefit of AAT augmentation therapy, evident by a decrease in circulating inflammation and controlled neutrophil adhesion.


  • Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis

    by Claudie Gabillard-Lefort, Michelle Casey, Arlene M. A. Glasgow, Fiona Boland, Orla Kerr, Elaine Marron, Anne-Marie Lyons, Cedric Gunaratnam, Noel G. McElvaney, Emer P. Reeves

    Rationale: Cystic fibrosis (CF) is caused by mutations in the CFTR (CF transmembrane conductance regulator) gene and is characterized by sustained inflammation. ATP triggers IL-1β secretion via P2X7R (P2X7 receptor) and activation of the NLRP3 (NOD-, LRR-, and pyrin domain–containing protein 3) inflammasome. Objectives: To explore the effect of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (Trikafta) on CFTR expression and the ATP/P2X7R signaling axis in monocytes and on circulating proinflammatory markers. Methods: Inflammatory mediators were detected in blood from 42 patients with CF before and after 3 months of Trikafta therapy. Markers of inflammasome activation and IL-1β secretion were measured in monocytes before and after stimulation with ATP and LPS, in the presence or absence of the P2X7R inhibitor A438079. Measurements and Main Results: P2X7R is overexpressed in CF monocytes, and receptor inhibition decreased NLRP3 expression, caspase-1 activation, and IL-1β secretion. In vitro and in vivo, P2X7R expression is regulated by CFTR function and intracellular chloride (Cl−) levels. Trikafta therapy restored CFTR expression yet decreased P2X7R in CF monocytes, resulting in normalized Cl− and potassium efflux, and reduced intracellular calcium levels. CFTR modulator therapy decreased circulating levels of ATP and LPS and reduced inflammasome activation and IL-1β secretion. Conclusions: P2X7R expression is regulated by intracellular Cl− levels and in CF monocytes promotes inflammasome activation. Trikafta therapy significantly increased CFTR protein expression and reduced ATP/P2X7R–induced inflammasome activation. P2X7R may therefore be a promising target for reducing inflammation in patients with CF who are noneligible for Trikafta or other CFTR modulator therapy.


  • Open Access

    Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

    by Daniel J. George, Jean-Francois Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, et al.

    Purpose: In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival (DFS) versus placebo in patients with loco-regional renal cell carcinoma at high risk of recurrence after nephrectomy. An exploratory analysis evaluated associations between single nucleotide polymorphisms (SNPs) in several angiogenesis- or hypoxia-related genes and clinical outcomes in S-TRAC. Experimental Design: Blood samples were genotyped for 10 SNPs and one insertion/deletion mutation using TaqMan assays. DFS was compared using log-rank tests for each genotype in sunitinib versus placebo groups and between genotypes within each of three (sunitinib, placebo, and combined sunitinib plus placebo) treatment groups. P-values were unadjusted. Results: In all, 286 patients (sunitinib, n=142; placebo, n=144) were genotyped. Longer DFS (HR [95% confidence interval]) was observed with sunitinib versus placebo for VEGFR1 rs9554320 C/C (0.44 [0.21-0.91]; P=0.023), VEGFR2 rs2071559 T/T (0.46 [0.23-0.90]; P=0.020), and eNOS rs2070744 T/T (0.53 [0.30-0.94]; P=0.028). Shorter DFS was observed for VEGFR1 rs9582036 C/A versus C/C with sunitinib, placebo, and combined therapies (P≤0.05), and A/A vs C/C with sunitinib (P=0.022). VEGFR1 rs9554320 A/C versus A/A was associated with shorter DFS in the placebo (P=0.038) and combined (P=0.006) groups. Conclusions: Correlations between VEGFR1 and VEGFR2 SNPs and longer DFS with sunitinib suggest germline SNPs are predictive of improved outcomes with adjuvant sunitinib in patients with renal cell carcinoma. Independent validation studies are needed to confirm these findings.


  • Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D + T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial

    by D. Schadendorf, M.M. Amonkar, D. Stroyakovskiy, E. Levchenko, H. Gogas, F.G.M. De Braud, J.-. Grob, I. Bondarenko, C. Garbe, C. Lebbe, et al.

    Aim: COMBI-d is a double-blinded, randomized phase III study (NCT01584648) that demonstrated a statistically significant improvement in PFS (HR = 0.75; 95% CI 0.57–0.99; P = 0.035), and overall response rate (ORR) (67% vs. 51%; P = 0.0015) for D + T vs. D in patients with BRAF V600E/K unresectable or metastatic melanoma. This analysis presents the impact of treatments on QOL. Methods: QOL was assessed using the EORTC QLQ-C30, a self-reporting generic cancer questionnaire (completed at baseline, during study treatment, at progression and post-progression). It assesses various dimensions, including global health/QOL, functional status and symptom impact. A mixed-model, repeated measures analyses of covariance assessed differences between arms. Results: Questionnaire completion rates (as % of available subjects) were >90% at baseline and at weeks 8, 16, 24 and 32, and 71% at progression. At baseline, patients in both treatment arms reported comparable scores for all dimensions. The global health/QOL dimension was consistently better (significantly at weeks 8, 16 and 24) for patients receiving D + T compared with those receiving D during treatment and at progression. For functional dimensions (physical, social, role, emotional, and cognitive functioning) the majority of scores trended in favor of patients receiving D + T. In terms of symptom impact, pain scores were significantly improved and clinically meaningful (6–13 point difference) for patients receiving D + T compared with those receiving D for all follow-up assessments. For other symptom dimensions (nausea and vomiting, diarrhea, dyspnea and constipation), scores trended in favor of D. Conclusions: In addition to the superior PFS and ORR of D + T vs. D, this analysis demonstrates that the combination provides further patient benefit based on global health/QOL and pain improvements. Disclosure: D. Schadendorf: D.S. has received case money from GSK. D.S. has received personal fees and non-financial support from GSK, Roche, Novartis, Amgen, Merck/MSD and received a grant from Merck/MSD M.M. Amonkar: M.M.A is an employee of GSK and owns stock in GSK; H. Gogas: H.G. has received personal fees from BMS, Roch, Merck, Novartis and Amgen; J.-. Grob: J-J.G. received personal fees from GSK, Roche, NMS, Merck, Celgene and Novartis; C. Garbe: C.G. has received grants and personal fees from GSK and Roche. C.G. has received personal fees from MSD, Novartis and Philogen; C. Lebbe: C.L. has received personal fees for participation in advisory boards from GSK, Roche, BMS and Novartis; J. Larkin: J.L. has received grants and personal fees from Novartis and Pfizer. J.L. has received personal fees from BMS and GSK; V. Chiarion-Sileni: V.C-S. has received fees from GSK, BMS and Roche for participating in advisory boards; M. Millward: M.M. has received clinical trial payments from GSK. M.M. has received personal fees for participating in an advisory board; A. Arance: A.A. has received a grant, personal fees and non-financial support from GSK. A.A. has received a grant and personal fees from Roche. A.A. has received personal fees from BMS; M. Casey: M.C. is an employee of GSK and owns stock in GSK; D.J. Demarini: D.J.DeM. is an employee of GSK. D.J.DeM. has an issued patent for Pharmaceutical Composition Containing Trametinib. D.J.DeM. has a patent pending for Combinations of Mekinist + gemcitabine; J. Irani: J.I. is an employee of GSK; G. Aktan: G.A. is an employee of GSK. G.A. owns stock in GSK; G.V. Long: Trial conducted at G.V.L.'s institution, sponsored by GSK. G.V.L. has received personal fees as a consultant advisor for Roche, GSK and Novartis. All other authors have declared no conflicts of interest.


  • METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).

    by Caroline Robert, Keith T. Flaherty, Peter Hersey, Paul D. Nathan, Claus Garbe, Mohammed M. Milhem, Lev V. Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, et al.

    LBA8509 The full, final text of this abstract will be available at asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.


  • Recommendations for capture, validation and summarisation of data from studies using RECIST

    by Melanie Paules, Michelle Casey, Grant Williams, R. Suzanne Swann, Philip S. Murphy, Vanessa M. Salazar, Diane Foose, Barbara Bailey, Patrick Therasse